pr-inside.com
Print

Research and Markets: A PharmaVitae Profile of Menarini: Examining Historical and Forecast Performance Data for Menarini's Performance in the Prescription Pharma Sector



2008-12-05 12:51:01 -

Research and Markets (www.researchandmarkets.com/research/472c4c/menarini_pharmavi) has announced the addition of the "Menarini: PharmaVitae Profile" company profile to their offering.
This analysis examines the historical and forecast performance for Menarini in the prescription pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Key reasons to purchase this title
- Benchmark Menarini's performance against key rivals in the prescription pharmaceutical sector
- Discover how the company's business model continues to drive sales growth across the established and emerging European markets
- Assess Menarini's position in the hypertension market and the various challenges that its broad antihypertensive portfolio could face
Key Topics Covered:
- Quarterly News Update
- Company Introduction
- Company Sales
- Company Financials
- Key Products and Competitors
- List of Tables
- List of Figures
Companies Mentioned:
- Abbott Laboratories
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Daiichi Sankyo, Ltd.
- GlaxoSmithKline Plc
- IMS Health
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis AG
- Novo Nordisk A/S
- Pfizer Inc
- Servier
- Taisho Pharmaceutical Co., Ltd.
For more information visit www.researchandmarkets.com/research/472c4c/menarini_pharmavi
Source: Datamonitor

Laura Wood

Senior Manager

press@researchandmarkets.com

Fax from USA: 646-607-1907

Fax from rest of the world: +353-1-481-1716



Press release: www.pr-inside.com
Contact Information: email




Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.